jRCT2080223342已完成3 期
CS-8958 Phase 3 study - A randomized, single-blind, placebo-controlled study of nebulized CS-8958 in the treatment of influenza virus infection -
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, randomized, single-blind, 2-parallel-group, placebo-controlled study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 10age old over 至 No limit（—）
- 性别
- All
入选标准
- •Tested positive for influenza A or B by the rapid diagnostic test
- •Body temperature (axillary) at informed consent >= 37.5 degrees
- •Within 36 hours of the onset of influenza symptoms at informed consent
排除标准
- •Suspected of having infection by bacteria species and/or other virus (pneumonia, bronchitis, otitis, sinusitis, etc.; including secondary infection) within 1 week before informed consent
- •History of influenza pneumonia
- •Assessed to be ineligible by the investigators, including those with serious complications
结局指标
主要结局
-
safety efficacy confirmatory Time to alleviation of influenza illness
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Study of nebulized CS-8958 (Pediatric Patients < 10 years of age)jRCT2080223343DAIICHI SANKYO Co.,Ltd.150
已完成
3 期
A Phase 3 Study of nebulized CS-8958 (Treatment of influenza)Influenza A or B virus infectionJPRN-jRCT2080223342DAIICHI SANKYO Co.,Ltd.534
未知
3 期
Add-on, open-label, phase III study of CS-866AZEssential hypertensionJPRN-jRCT2080220290DAIICHISANKYO Co.,Ltd.
未知
3 期
Open-label, phase III study of CS-866AZEssential hypertensionJPRN-jRCT2080220439DAIICHISANKYO Co.,Ltd.
已完成
3 期
A Phase 3 Study of nebulized CS-8958 (Pediatric Patients < 10 years of age)Influenza A or B virus infectionJPRN-jRCT2080223343DAIICHI SANKYO Co.,Ltd.173